Literature DB >> 10553103

CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7.

H Höhn1, H Pilch, S Günzel, C Neukirch, C Hilmes, A Kaufmann, B Seliger, M J Maeurer.   

Abstract

Human papillomavirus (HPV)-encoded proteins may provide targets for CD8+ or CD4+ T lymphocytes infiltrating into cervical cancer. We established an MHC class II-restricted CD4+ T cell line from a patient with cervical cancer that recognizes autologous (HPV35+, HPV59+) cervical cancer cells and the HLA-DR4-matched cervical cancer cell line Me180 (HPV68+) as determined by TNF-alpha secretion. Expression of different HPV-E7 genes in autologous B cells revealed that this T cell line defines a DR4-presented T cell epitope that is shared among the E7 genes of HPV59 and HPV68. MHC class II-presented peptides may be implemented to augment T cell responses directed against autologous tumor cells, particularly if cancer cells lack MHC class I expression, which is a frequent event in the evolution of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

3.  Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Authors:  Benjamin Y Jin; Tracy E Campbell; Lindsey M Draper; Sanja Stevanović; Bianca Weissbrich; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Cornelia L Trimble; Christian S Hinrichs
Journal:  JCI Insight       Date:  2018-04-19

4.  Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.

Authors:  H Höhn; H Pilch; S Günzel; C Neukirch; K Freitag; A Necker; M J Maeurer
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.

Authors:  María de Lourdes Mora-García; Alfonso Duenas-González; Jorge Hernández-Montes; Erick De la Cruz-Hernández; Enrique Pérez-Cárdenas; Benny Weiss-Steider; Edelmiro Santiago-Osorio; Vianney Francisco Ortíz-Navarrete; Víctor Hugo Rosales; David Cantú; Marcela Lizano-Soberón; Martha Patricia Rojo-Aguilar; Alberto Monroy-García
Journal:  J Transl Med       Date:  2006-12-27       Impact factor: 5.531

7.  Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.

Authors:  Liliane Maria Fernandes de Oliveira; Mirian Galliote Morale; Agatha A Muniz Chaves; Aline Marques Cavalher; Aline Soriano Lopes; Mariana de Oliveira Diniz; Alessandra Soares Schanoski; Robson Lopes de Melo; Luís Carlos de Souza Ferreira; Maria Leonor S de Oliveira; Marilene Demasi; Paulo Lee Ho
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

8.  [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.

Authors:  Fernanda G Herrera; Thomas Breuneval; John O Prior; Jean Bourhis; Mahmut Ozsahin
Journal:  Radiat Oncol       Date:  2016-03-16       Impact factor: 3.481

9.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.